Photo-Activated Psoralen Binds the ErbB2 Catalytic Kinase Domain, Blocking ErbB2 Signaling and Triggering Tumor Cell Apoptosis

ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system

(2013) Sigrun Polier et al.   Nature Chemical Biology

Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein

(2011) Kathleen Aertgeerts et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Truncated ErbB2 Expressed in Tumor Cell Nuclei Contributes to Acquired Therapeutic Resistance to ErbB2 Kinase Inhibitors

(2011) W. Xia et al.   MOLECULAR CANCER THERAPEUTICS

Management of breast cancer with targeted agents: importance of heterogenicity

(2010) Serena Di Cosimo et al.   Nature Reviews Clinical Oncology

Histone Deacetylase Inhibitor Sodium Butyrate Enhances the Cell Killing Effect of Psoralen plus UVA by Attenuating Nucleotide Excision Repair

(2009) T. Toyooka et al.   CANCER RESEARCH

Phase II Study of Predictive Biomarker Profiles for Response Targeting Human Epidermal Growth Factor Receptor 2 (HER-2) in Advanced Inflammatory Breast Cancer With Lapatinib Monotherapy

(2008) Stephen Johnston et al.   JOURNAL OF CLINICAL ONCOLOGY